{
    "nct_id": "NCT01559220",
    "title": "Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2017-03-28",
    "description_brief": "The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS)as a treatment option for patients with cognitive, behavioral, and functional disability of Alzheimer's disease.",
    "description_detailed": "Open label pilot study\n\n* Expected direct benefit on the modulation of neuronal networks.\n* Expected indirect benefit via potential enhancements of memory, executive functions, cognition behavioral control, and functional abilities.\n\nUp to 10 subjects will be implanted with bilateral DBS systems, participants are expected to be on study for about 23 months.\n\n* Develop a multidisciplinary clinical research protocol to evaluate the efficacy of ventral striatum, nucleus accumbens, and internal capsule for the amelioration of disability caused by Alzheimer's Disease.\n* Enroll up to 10 patients into an open label study to evaluate the safety and efficacy of DBS for Alzheimer's Disease patients with mild to moderate disability.\n* Determine an initial DBS titration and stimulation settings protocol for use in subsequent controlled trials.\n* Evaluate the outcomes of this study based on clinical, laboratory, biomarker, imaging, cognitive, behavioral, and functional assessments.\n* Determine what domains of cognitive, behavioral and functioning impairment show the greatest response to DBS.\n* Examine the potential benefit of stimulation combined with behavioral and rehabilitation interventions in comparison to stimulation alone.\n* Evaluate the influence of DBS on physiological and functional changes in cortical and subcortical networks.",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "DEVICE_FEASIBILITY",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Deep Brain Stimulation (DBS) \u2014 device neuromodulation (reported targets in this and related AD trials: ventral striatum / nucleus accumbens / internal capsule; other published DBS-for-AD work targeted the fornix and nucleus basalis of Meynert)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is deep brain stimulation (DBS), a neuromodulation device intended to improve cognitive, behavioral, and functional abilities in Alzheimer's disease rather than a biologic or small-molecule drug. The trial title and brief description emphasize improving cognition/memory, executive function and functional abilities, which aligns with the category 'cognitive enhancer' (intervention aimed at improving cognitive function). \ue200cite\ue202turn0search3\ue202turn0search2\ue201",
        "Act: Key extracted details from the trial description and public records \u2014 (1) Intervention: Device \u2014 Deep Brain Stimulation (DBS). (2) Indication/intent: treatment of cognitive, behavioral, and functional disability in Alzheimer's disease (aims include memory, executive functions, cognition, behavioral control, and functional abilities). (3) Targets noted in trial records: ventral striatum / nucleus accumbens / internal capsule for this study; related published DBS-for-AD work frequently targeted the fornix and nucleus basalis of Meynert. These details identify this as a neuromodulation (device) cognitive intervention rather than a biologic or small molecule. \ue200cite\ue202turn0search3\ue202turn0search2\ue202turn0search0\ue201",
        "Web search results (selected sources found): (a) Clinical trial record summary for NCT01559220 describing DBS for treatment of cognitive, behavioral, and functional disability in AD; lists DBS as the intervention and mentions targets (ventral striatum/nucleus accumbens/internal capsule) and open-label pilot design. \ue200cite\ue202turn0search3\ue202turn0search10\ue201 (b) Phase I human trial of fornix/hypothalamus DBS in mild AD reporting feasibility, metabolic and cognitive assessments. \ue200cite\ue202turn0search2\ue201 (c) Systematic reviews and reviews summarizing DBS as an experimental neuromodulation approach for AD, noting targets (fornix, nucleus basalis of Meynert, ventral striatum) and mixed/limited evidence for cognitive benefit so far. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search6\ue201",
        "Reflect: Classification check \u2014 DBS is a therapeutic device (not a biologic or small molecule). The primary stated goal is to improve cognition/functional ability (with behavioral aspects included). Under the provided category definitions, the best fit is 'cognitive enhancer' because the intervention aims to improve cognitive function rather than targeting amyloid/tau pathology (disease-targeted biologic or small molecule) or solely treating neuropsychiatric symptoms. Note: the trial also explicitly targets behavioral control (overlap with neuropsychiatric symptom improvement), so there is some cross-over; however the dominant, stated intent (and common framing of DBS-for-AD literature) is circuit-based improvement of cognition/memory, supporting the 'cognitive enhancer' label. \ue200cite\ue202turn0search3\ue202turn0search0\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: The intervention is deep brain stimulation (DBS), a neuromodulation device intended to modulate dysfunctional neural circuits to improve cognition, memory and functional abilities in AD rather than targeting an amyloid/tau molecular pathway. DBS's proposed mechanisms include circuit-level modulation, enhancement of network activity and possible effects on neurogenesis and synaptic function\u2014consistent with synaptic plasticity/neuroprotection. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Act: Extracted trial details: (1) Intervention: Device \u2014 Deep Brain Stimulation (DBS). (2) Intent: improve cognitive, behavioral and functional disability in Alzheimer's disease. (3) Reported/studied anatomical targets include the fornix, nucleus basalis of Meynert (NBM), ventral striatum / nucleus accumbens / internal capsule in related trials. These features identify this as a circuit/neuromodulation approach aimed at improving synaptic/circuit function (cognitive enhancement) rather than a molecular disease-modifying target such as amyloid or tau. \ue200cite\ue202turn0search3\ue202turn0search5\ue201",
        "Reflect: Mapping to CADRO \u2014 there is no separate CADRO category explicitly for device neuromodulation; the most specific fit for an intervention whose goal is to enhance cognition by modulating circuits and supporting synaptic/network function is M) Synaptic Plasticity/Neuroprotection. The intervention is therapeutic (not diagnostic), focused on circuit and synaptic function rather than inflammation, metabolism, amyloid, tau, or other single molecular pathways, so 'M' is the best match. If one prioritized a strictly non-pharmacologic/device category, CADRO does not provide one, so 'T) Other' would be inappropriate here. \ue200cite\ue202turn0search7\ue202turn0search2\ue201",
        "Web search results (selected sources used to support the classification): (a) Phase II randomized sham-controlled trial of fornix DBS in mild AD (NCT01608061) \u2014 reports safety, metabolic/network effects but no group-level cognitive benefit at 12 months. \ue200cite\ue202turn0search3\ue201 (b) Reviews and mechanistic discussion of DBS as a circuit-based intervention for memory and cognition in AD (discussing targets such as fornix, NBM, ventral striatum and proposed synaptic/network mechanisms). \ue200cite\ue202turn0search4\ue202turn0search1\ue201 (c) Systematic reviews/meta-analyses summarizing the small, heterogeneous clinical literature on DBS in AD and listing common targets (fornix, NBM, ventral striatum) and mixed/limited evidence for cognitive benefit so far. \ue200cite\ue202turn0search7\ue202turn0search5\ue201"
    ]
}